Core Viewpoint - Actuate Therapeutics, Inc. has successfully closed a public offering, raising $17.25 million through the sale of 2,464,286 shares of common stock, with a public offering price of $7.00 per share [1]. Company Overview - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β) [5]. - The company's lead investigational drug, elraglusib, targets molecular pathways that promote tumor growth and resistance to conventional cancer treatments, potentially enhancing anti-tumor immunity [5]. Financial Details - The net proceeds from the offering are approximately $15.62 million, which will be used for working capital and general corporate purposes [2]. - The offering was managed by Lucid Capital Markets, with Titan Partners Group acting as a financial advisor [2]. Regulatory Information - The common stock was offered under a shelf registration statement on Form S-3, which has been declared effective by the SEC [3]. - A final prospectus supplement related to the offering has been filed with the SEC and is available on their website [3].

Core Viewpoint - Actuate Therapeutics, Inc. has announced a public offering of 2,142,858 shares of common stock at a price of $7.00 per share, aiming to raise approximately $15.0 million for working capital and general corporate purposes [1][3]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 321,428 shares at the public offering price [1]. - Lucid Capital Markets is the sole book-running manager, while Titan Partners Group serves as the financial advisor for the offering [2]. Group 2: Financial Information - The gross proceeds from the offering are expected to be around $15.0 million before deducting underwriting discounts and commissions [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on therapies for high-impact, difficult-to-treat cancers, specifically through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [6]. - The lead investigational drug, elraglusib, targets molecular pathways that promote tumor growth and resistance to conventional cancer treatments [6].